ERBB2 and breast cancer: Clinically, this heterogeneous disease is categorized into the three following therapeutic groups (5): Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-amplified and triple-negative BC [lacking ER, progesterone receptor (PR) and HER2].